
The late-stage pipeline for non-Hodgkin’s lymphoma (NHL) contains a diverse range of mechanisms of action.
Non-Hodgkin’s lymphoma treatment
The figure below displays ongoing trials for agents seeking a first approval in NHL. Of the seven therapies, two are targeting CD19 (Celgene’s lisocabtagene maraleucel and MorphoSys’ tafasitamab) while the remaining five each work against different targets.
Combination therapies are the norm in NHL treatment, and the pipeline reflects that as lisocabtagene maraleucel and Amgen’s Blincyto are the only therapies being investigated as monotherapies, while the remainder is being investigated in combination with other therapies.
Roche’s Polivy (polatuzumab vedotin-piiq) was recently approved by the US Food and Drug Administration (FDA), in June 2019, in combination with bendamustine and rituximab. GlobalData believes TG Therapeutics’ U2 regimen (ublituximab + umbralisib) will be the next therapy to achieve an FDA approval, in 2020.
Source: GlobalData © GlobalData
CMR = complete metabolic response; DLT =dose-limiting toxicities ; EFS = event-free survival; ORR = overall response rate; OS = overall survival; PCD = primary completion date; PFS = progression-free survival; TLS = tumor lysis syndrome